(Q46156546)

20 December 2017

title

Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude (English)

1 reference

20 December 2017

1 reference

4

Chantal Kemner

1 reference

20 December 2017

6

René S Kahn

1 reference

20 December 2017

author name string

Bob Oranje

1

1 reference

20 December 2017

Christine C Gispen-de Wied

2

1 reference

20 December 2017

Herman G M Westenberg

3

1 reference

20 December 2017

Marinus N Verbaten

5

1 reference

20 December 2017

publication date

21 January 2009

1 reference

20 December 2017

The International Journal of Neuropsychopharmacology

published in

1 reference

20 December 2017

volume

12

1 reference

20 December 2017

issue

6

1 reference

20 December 2017

page(s)

823-832

1 reference

20 December 2017

Stereoselective high-performance liquid chromatographic determination of the enantiomers of ketamine and norketamine in plasma

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Neurochemical substrates and neuroanatomical generators of the event-related P300.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

A diagnostic interview: the schedule for affective disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

CSF monoamine metabolites in patients and controls: support for a bimodal distribution in major affective disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

P300 delay and attenuation in schizophrenia: reversal by neuroleptic medication.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Auditory selective attention and event-related potentials in schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Meta-analysis of the P300 and P50 waveforms in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Auditory evoked potentials, clinical vs. research applications

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Schizophrenia: a neurophysiological evaluation of abnormal information processing

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

The effect of decreased catecholamine transmission on ERP indices of selective attention

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

The principal features and mechanisms of dopamine modulation in the prefrontal cortex

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Some features of the auditory evoked response in schizophrenics.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

The effects of a sub-anaesthetic dose of ketamine on human selective attention.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

No effects of l-dopa and bromocriptine on psychophysiological parameters of human selective attention

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Effects of intravenous L-dopa on P300 and regional cerebral blood flow in parkinsonism.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Electroencephalographic characterization of brain dopaminergic stimulation by apomorphine in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Striatal and frontal cortex binding of 11-C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Removal of the ocular artifact from the EEG: a comparison of time and frequency domain methods with simulated and real data

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Subanesthetic doses of ketamine stimulate psychosis in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Effects of haloperidol on selective attention: a combined whole-head MEG and high-resolution EEG study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Neurophysiological biomarkers for drug development in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Electrical signs of selective attention in the human brain

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

Catecholamines and attention. II: Pharmacological studies in normal humans

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009814

7 January 2021

10.1017/S1461145708009814

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017